These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24748388)

  • 1. Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease.
    Tuñón J; Cristóbal C; Tarín N; Aceña Á; González-Casaus ML; Huelmos A; Alonso J; Lorenzo Ó; González-Parra E; Mahíllo-Fernández I; Pello AM; Carda R; Farré J; Rodríguez-Artalejo F; López-Bescós L; Egido J
    PLoS One; 2014; 9(4):e95402. PubMed ID: 24748388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sun exposure influences the prognostic power of components of mineral metabolism in patients with coronary artery disease.
    Aceña A; Franco-Peláez JA; Gutierrez-Landaluce C; Pello AM; Cristóbal C; Tarín N; Huelmos A; Carda R; Martín-Mariscal ML; Alonso J; González-Parra E; González-Casaus ML; Lorenzo Ó; López Bescos L; Egido J; Tuñón J
    Nutr Metab Cardiovasc Dis; 2017 Sep; 27(9):762-767. PubMed ID: 28803689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating fibroblast growth factor-23 plasma levels predict adverse cardiovascular outcomes in patients with diabetes mellitus with coronary artery disease.
    Tuñón J; Fernández-Fernández B; Carda R; Pello AM; Cristóbal C; Tarín N; Aceña Á; González-Casaus ML; Huelmos A; Alonso J; Lorenzo Ó; González-Parra E; Hernández-González I; Mahíllo-Fernández I; López-Bescós L; Egido J
    Diabetes Metab Res Rev; 2016 Oct; 32(7):685-693. PubMed ID: 26888181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential profile in inflammatory and mineral metabolism biomarkers in patients with ischemic heart disease without classical coronary risk factors.
    Pello AM; Cristóbal C; Tarín N; Huelmos A; Aceña Á; Carda R; González-Casaus ML; Alonso J; Lorenzo Ó; Blanco-Colio L; Martín-Ventura JL; Franco Peláez JA; Mahíllo-Fernández I; Farré J; López-Bescós L; Egido J; Tuñón J
    J Cardiol; 2015 Jul; 66(1):22-7. PubMed ID: 25533425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parathormone levels add prognostic ability to N-terminal pro-brain natriuretic peptide in stable coronary patients.
    Gutiérrez-Landaluce C; Aceña Á; Pello A; Martínez-Milla J; González-Lorenzo Ó; Tarín N; Cristóbal C; Blanco-Colio LM; Martín-Ventura JL; Huelmos A; López-Castillo M; Alonso J; López Bescós L; Alonso-Pulpón L; González-Parra E; Egido J; Mahíllo-Fernández I; Lorenzo Ó; González-Casaus ML; Tuñón J
    ESC Heart Fail; 2021 Aug; 8(4):2713-2722. PubMed ID: 33932116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma Levels of Monocyte Chemoattractant Protein-1, n-Terminal Fragment of Brain Natriuretic Peptide and Calcidiol Are Independently Associated with the Complexity of Coronary Artery Disease.
    Martín-Reyes R; Franco-Peláez JA; Lorenzo Ó; González-Casaus ML; Pello AM; Aceña Á; Carda R; Martín-Ventura JL; Blanco-Colio L; Martín-Mariscal ML; Martínez-Milla J; Villa-Bellosta R; Piñero A; Navarro F; Egido J; Tuñón J
    PLoS One; 2016; 11(5):e0152816. PubMed ID: 27171378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor 23 independently predicts adverse outcomes after an acute coronary syndrome.
    Kallmeyer A; Pello A; Cánovas E; Aceña Á; González-Casaus ML; Tarín N; Cristóbal C; Gutiérrez-Landaluce C; Huelmos A; Rodríguez-Valer A; González-Lorenzo Ó; Alonso J; López-Bescós L; Egido J; Mahillo I; Lorenzo Ó; Tuñón J
    ESC Heart Fail; 2024 Feb; 11(1):240-250. PubMed ID: 37950429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum level of fibroblast growth factor 21 predicts long-term prognosis in patients with both diabetes mellitus and coronary artery calcification.
    Gan F; Huang J; Dai T; Li M; Liu J
    Ann Palliat Med; 2020 Mar; 9(2):368-374. PubMed ID: 32268770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial.
    Bergmark BA; Udell JA; Morrow DA; Cannon CP; Steen DL; Jarolim P; Budaj A; Hamm C; Guo J; Im K; Kuder JF; Braunwald E; Sabatine MS; O'Donoghue ML
    JAMA Cardiol; 2018 Jun; 3(6):473-480. PubMed ID: 29710336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate.
    González-Parra E; Aceña Á; Lorenzo Ó; Tarín N; González-Casaus ML; Cristóbal C; Huelmos A; Mahíllo-Fernández I; Pello AM; Carda R; Hernández-González I; Alonso J; Rodríguez-Artalejo F; López-Bescós L; Ortiz A; Egido J; Tuñón J
    J Bone Miner Metab; 2016 Sep; 34(5):587-98. PubMed ID: 26298279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The fibroblast growth factor-23 and Vitamin D emerge as nontraditional risk factors and may affect cardiovascular risk.
    Masson S; Agabiti N; Vago T; Miceli M; Mayer F; Letizia T; Wienhues-Thelen U; Mureddu GF; Davoli M; Boccanelli A; Latini R;
    J Intern Med; 2015 Mar; 277(3):318-330. PubMed ID: 24620922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of renal function on the prognostic value of mineral metabolism in patients with chronic ischaemic heart disease patients with chronic ischaemic heart disease.
    Aceña Á; Pello-Lázaro AM; Martínez-Milla J; González-Lorenzo Ó; Tarín N; Cristóbal C; Blanco-Colio LM; Martín-Ventura JL; Huelmos A; López-Castillo M; Alonso J; Gutiérrez-Landaluce C; López Bescós L; Alonso-Pulpón L; González-Parra E; Egido J; Mahíllo-Fernández I; Lorenzo Ó; González-Casaus ML; Tuñón J
    Clin Investig Arterioscler; 2022; 34(1):1-9. PubMed ID: 34876305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.
    Isakova T; Xie H; Yang W; Xie D; Anderson AH; Scialla J; Wahl P; Gutiérrez OM; Steigerwalt S; He J; Schwartz S; Lo J; Ojo A; Sondheimer J; Hsu CY; Lash J; Leonard M; Kusek JW; Feldman HI; Wolf M;
    JAMA; 2011 Jun; 305(23):2432-9. PubMed ID: 21673295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-Biomarkers-Clinical Risk Factors for Prediction of Cardiovascular Events in Patients With Coronary Artery Disease.
    Wong YK; Cheung CYY; Tang CS; Au KW; Hai JSH; Lee CH; Lau KK; Cheung BMY; Sham PC; Xu A; Lam KSL; Tse HF
    Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2519-2527. PubMed ID: 30354221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inorganic phosphate and FGF-23 predict outcome in stable systolic heart failure.
    Plischke M; Neuhold S; Adlbrecht C; Bielesz B; Shayganfar S; Bieglmayer C; Szekeres T; Hörl WH; Strunk G; Vavken P; Pacher R; Hülsmann M
    Eur J Clin Invest; 2012 Jun; 42(6):649-56. PubMed ID: 22150123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease.
    Udell JA; Morrow DA; Jarolim P; Sloan S; Hoffman EB; O'Donnell TF; Vora AN; Omland T; Solomon SD; Pfeffer MA; Braunwald E; Sabatine MS
    J Am Coll Cardiol; 2014 Jun; 63(22):2421-8. PubMed ID: 24727254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast Growth Factor 23 and α-Klotho Protein Are Associated with Adverse Clinical Outcomes in Non-Dialysis CKD Patients.
    Manou E; Thodis E; Arsos G; Pasadakis P; Panagoutsos S; Papadopoulou D; Papagianni A
    Kidney Blood Press Res; 2020; 45(6):900-915. PubMed ID: 33040068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD.
    Smith K; deFilippi C; Isakova T; Gutiérrez OM; Laliberte K; Seliger S; Kelley W; Duh SH; Hise M; Christenson R; Wolf M; Januzzi J
    Am J Kidney Dis; 2013 Jan; 61(1):67-73. PubMed ID: 22883134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease.
    Kanbay M; Nicoleta M; Selcoki Y; Ikizek M; Aydin M; Eryonucu B; Duranay M; Akcay A; Armutcu F; Covic A
    Clin J Am Soc Nephrol; 2010 Oct; 5(10):1780-6. PubMed ID: 20576822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Fibroblast Growth Factor-23 Levels and Angiotensin-Converting Enzyme Inhibition in Chronic Systolic Heart Failure.
    Wohlfahrt P; Melenovsky V; Kotrc M; Benes J; Jabor A; Franekova J; Lemaire S; Kautzner J; Jarolim P
    JACC Heart Fail; 2015 Oct; 3(10):829-39. PubMed ID: 26450001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.